tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target
PremiumRatingsMerus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target
1M ago
Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability
Premium
Ratings
Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability
1M ago
Merus Announces Public Offering of Common Shares
Premium
Company Announcements
Merus Announces Public Offering of Common Shares
1M ago
Merus announces common shares offering, no amount given
PremiumThe FlyMerus announces common shares offering, no amount given
2M ago
Merus’s Strong Clinical Data and Financial Stability Justify Buy Rating
Premium
Ratings
Merus’s Strong Clinical Data and Financial Stability Justify Buy Rating
2M ago
Merus Announces Promising Phase 2 Trial Results
Premium
Company Announcements
Merus Announces Promising Phase 2 Trial Results
2M ago
Merus price target raised to $110 from $96 at BMO Capital
PremiumThe FlyMerus price target raised to $110 from $96 at BMO Capital
2M ago
Merus price target raised to $92 from $70 at BofA
Premium
The Fly
Merus price target raised to $92 from $70 at BofA
2M ago
Promising Potential of Merus’s Petosemtamab: A Buy Rating Backed by Impressive Efficacy and Safety
Premium
Ratings
Promising Potential of Merus’s Petosemtamab: A Buy Rating Backed by Impressive Efficacy and Safety
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100